|October 29, 2021|
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Synthetic Biologics, Inc.
Registration Statement on Form S-3
File No: 333-260449
Request For Acceleration
Ladies and Gentlemen:
Synthetic Biologics, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-260449), to become effective on Tuesday, November 2, 2021, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. or Patrick J. Egan, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457 or Mr. Egan at (914) 557-5574 or (212) 907-6457 with any questions you may have concerning this request, and please notify her or him when this request for acceleration has been granted.
|Very truly yours,|
|Synthetic Biologics, Inc.|
|By:||/s/ Steven A. Shallcross|
|Name: Steven A. Shallcross|
|Title: Chief Executive Officer and Chief Financial Officer|
Leslie Marlow, Esq., Gracin & Marlow, LLP
Patrick J. Egan, Esq., Gracin & Marlow, LLP